- Home
- PHGE vs GXAI Comparison
PHGE vs GXAI Comparison
Compare PHGE & GXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- GXAI
- Stock Information
- Founded
- PHGE 2015
- GXAI 2021
- Country
- PHGE Israel
- GXAI United States
- Employees
- PHGE N/A
- GXAI N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- GXAI
- Sector
- PHGE Health Care
- GXAI
- Exchange
- PHGE Nasdaq
- GXAI Nasdaq
- Market Cap
- PHGE 13.3M
- GXAI 11.3M
- IPO Year
- PHGE N/A
- GXAI 2023
- Fundamental
- Price
- PHGE $0.96
- GXAI $1.41
- Analyst Decision
- PHGE Strong Buy
- GXAI
- Analyst Count
- PHGE 2
- GXAI 0
- Target Price
- PHGE $13.50
- GXAI N/A
- AVG Volume (30 Days)
- PHGE 48.8K
- GXAI 565.3K
- Earning Date
- PHGE 04-02-2025
- GXAI 03-26-2025
- Dividend Yield
- PHGE N/A
- GXAI N/A
- EPS Growth
- PHGE N/A
- GXAI N/A
- EPS
- PHGE N/A
- GXAI N/A
- Revenue
- PHGE N/A
- GXAI $2,979.00
- Revenue This Year
- PHGE N/A
- GXAI N/A
- Revenue Next Year
- PHGE N/A
- GXAI N/A
- P/E Ratio
- PHGE N/A
- GXAI N/A
- Revenue Growth
- PHGE N/A
- GXAI N/A
- 52 Week Low
- PHGE $0.48
- GXAI $1.01
- 52 Week High
- PHGE $8.55
- GXAI $16.27
- Technical
- Relative Strength Index (RSI)
- PHGE 65.22
- GXAI 39.78
- Support Level
- PHGE $0.87
- GXAI $1.41
- Resistance Level
- PHGE $0.99
- GXAI $2.00
- Average True Range (ATR)
- PHGE 0.08
- GXAI 0.17
- MACD
- PHGE 0.01
- GXAI 0.03
- Stochastic Oscillator
- PHGE 89.20
- GXAI 9.23
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.